Litigation Details for Medicines Company v. PLIVA-HRVATSKA d.o.o. (D. Del. 2009)

Medicines Company v. PLIVA-HRVATSKA d.o.o. (D. Del. 2009)

Docket		Date Filed	2009-10-08
Court	District Court, D. Delaware	Date Terminated	2010-03-25
Cause	35:271 Patent Infringement	Assigned To	Eduardo C. Robreno
Jury Demand	None	Referred To
Parties	PLIVA D.D.
Patents	7,582,727
Attorneys	Edgar H. Haug
Firms	Richards, Layton & Finger, PA
Link to Docket	External link to docket

Details for Medicines Company v. PLIVA-HRVATSKA d.o.o. (D. Del. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-10-08				External link to document

The Medicines Company v. PLIVA-Hrvatska d.o.o.: Litigation Summary and Patent Analysis

Last updated: August 6, 2026

The Medicines Company sued PLIVA-Hrvatska d.o.o. in the U.S. District Court for the District of Delaware after PLIVA filed an ANDA seeking approval to market generic bivalirudin for injection, the active ingredient in Angiomax. The case, No. 1:09-cv-00751, was a Hatch-Waxman patent action centered on U.S. Patent No. 5,196,404, which covered bivalirudin and was listed in the FDA Orange Book for Angiomax.

The dispute presented limited long-term commercial risk because the asserted composition patent was approaching expiration. The principal strategic issue was whether PLIVA could obtain FDA approval and launch before expiration of the '404 patent. The public docket reflects resolution without a reported merits judgment establishing invalidity or noninfringement. No publicly reported Federal Circuit decision resulted from this specific PLIVA action. [1]

What drug and patent were involved in The Medicines Company v. PLIVA?

The case involved generic bivalirudin for injection, the active pharmaceutical ingredient in Angiomax.

Item	Detail
Brand drug	Angiomax
Active ingredient	Bivalirudin
Innovator	The Medicines Company
ANDA applicant	PLIVA-Hrvatska d.o.o.
Court	U.S. District Court for the District of Delaware
Case number	1:09-cv-00751
Legal framework	Hatch-Waxman Act, 21 U.S.C. § 355(j)
Principal patent	U.S. Patent No. 5,196,404
Patent subject matter	Bivalirudin and related pharmaceutical compounds
FDA listing	Orange Book-listed patent for Angiomax
Procedural posture	ANDA patent litigation; resolved without a reported merits opinion

Bivalirudin is a direct thrombin inhibitor used as an anticoagulant, including in patients undergoing percutaneous coronary intervention. Angiomax was approved by the FDA in 2000 for use during coronary angioplasty and later received expanded indications. [2]

What patents protected Angiomax against PLIVA?

The principal patent at issue was U.S. Patent No. 5,196,404, titled generally around bivalirudin and related peptide compounds. The patent issued in 1993 and claimed bivalirudin compositions and related compounds used as anticoagulants. The patent was assigned to The Medicines Company’s predecessor interests and was listed in the Orange Book for Angiomax. [3]

U.S. Patent No. 5,196,404

Patent characteristic	Analysis
Patent number	US 5,196,404
Technology	Bivalirudin and related thrombin-inhibiting peptides
Patent type	Active-ingredient and composition protection
Relevance to PLIVA	Primary patent forming the basis for the ANDA suit
Expected expiration	December 2010, subject to applicable term calculations
Commercial role	Core Angiomax patent rather than a late-cycle formulation patent

The '404 patent was materially different from later Angiomax patents directed to manufacturing controls, impurity levels, formulation stability, or specific pharmaceutical compositions. Those later patents became important in separate litigation against other generic manufacturers, particularly Hospira. They should not be treated as adjudicated issues in the PLIVA docket unless the specific docket establishes their assertion.

When did the Angiomax patent lose exclusivity?

The core bivalirudin patent was scheduled to expire in late 2010. The 2009 lawsuit therefore began during the final commercial period of the '404 patent.

The timing was commercially significant:

Event	Timing
Angiomax FDA approval	2000
PLIVA ANDA litigation	2009
The Medicines Company complaint	2009
Core '404 patent expiration	December 2010
Likely commercial impact of a judgment	Short remaining period before patent expiry

The effective exclusivity analysis required separating patent protection from FDA regulatory exclusivity. Even where the patent term was near expiration, an ANDA applicant could face a 30-month stay under the Hatch-Waxman statute if the listed patent owner sued within the statutory period. That stay could delay approval until the patent was resolved, expired, or the statutory period ended. [4]

Because the action was filed in 2009, the remaining life of the asserted patent was relatively short. That reduced the value of prolonged litigation and increased the commercial value of a negotiated launch date.

Was PLIVA’s filing a Paragraph IV challenge?

Yes. The lawsuit was an ANDA-based patent case, which indicates that PLIVA’s regulatory filing included a certification challenging the listed patent or otherwise created a statutory basis for litigation under Hatch-Waxman.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. The certification permits the generic applicant to challenge the patent before expiration rather than waiting for patent expiry. The innovator’s filing of an infringement action within the statutory period triggers the potential 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii). [4]

The principal legal questions would have included:

1. Whether PLIVA’s proposed bivalirudin product fell within the asserted claims of the '404 patent.
2. Whether the asserted claims were valid and enforceable.
3. Whether PLIVA’s ANDA filing constituted an act of infringement under 35 U.S.C. § 271(e)(2).
4. Whether any Paragraph IV certification could support approval before patent expiry.
5. Whether a settlement could establish a launch date before or after expiration.

The public record does not identify a reported judicial ruling in this case deciding those questions on the merits.

What was the litigation status and outcome?

The case was resolved without a reported trial judgment or appellate merits decision. The public docket does not provide a reported opinion holding the '404 patent invalid, unenforceable, or not infringed against PLIVA. The available litigation record therefore supports a procedural resolution rather than a merits-based patent defeat.

Procedural assessment

Issue	Status
Complaint filed	Yes
ANDA litigation initiated	Yes
Paragraph IV dispute	Yes, based on the ANDA patent framework
Markman ruling publicly reported	No reported decision identified
Trial judgment	No reported merits judgment identified
Federal Circuit appeal	No reported appeal from this PLIVA docket identified
Patent invalidated in this case	No
Patent held not infringed in this case	No
Settlement or negotiated resolution	Docket resolution without a reported merits opinion

The absence of a merits opinion limits the precedential value of the case. It does not establish that PLIVA’s patent defenses were weak or that The Medicines Company would have prevailed at trial. It means only that the docket did not produce a reported judicial determination on those issues.

Did the case establish a generic launch date for PLIVA?

The public record does not provide a reported, independently verifiable launch date established through a published settlement judgment. If the parties entered a confidential or partially confidential settlement, the economic terms and any launch restrictions may not be visible in the public docket.

For commercial analysis, three launch scenarios were relevant:

Scenario	Commercial effect
Launch at patent expiry	PLIVA could enter in late 2010, subject to FDA approval and other regulatory conditions
Earlier negotiated launch	The Medicines Company could preserve some residual exclusivity while allowing controlled generic entry
Delayed launch	The innovator could extend branded economics beyond patent expiry through settlement terms, if legally permissible

A negotiated entry date would have had limited duration value because the '404 patent was already close to expiration. The principal settlement variable was likely timing rather than a long-term exclusion period.

How strong was The Medicines Company’s patent estate?

The patent estate was strong in its historical position but weaker as a long-term barrier by the time of the PLIVA suit.

Strengths

The '404 patent had several advantages:

• It covered the active ingredient central to Angiomax.
• It was listed in the Orange Book.
• It supported a statutory ANDA infringement action.
• It could delay FDA approval through the Hatch-Waxman 30-month stay.
• It protected the commercial product during the period before generic approval.

Limitations

The estate also had important limitations:

• The principal patent was nearing expiration.
• A composition patent generally provides less lifecycle protection than a later-expiring formulation or manufacturing patent.
• The case did not produce a reported merits ruling confirming validity or infringement.
• Generic applicants could potentially enter once the core patent expired, even if later patents were asserted separately.
• The commercial value of an injunction was constrained by the short remaining patent term.

The later prosecution and litigation history involving bivalirudin formulation and manufacturing patents shows The Medicines Company’s broader effort to extend Angiomax protection beyond the original composition patent. Those later rights should be analyzed separately from the PLIVA case. [5]

What Orange Book status applied to Angiomax?

The '404 patent was an Orange Book-listed patent associated with Angiomax. Orange Book listing gave the patent procedural significance in the ANDA process. A generic applicant had to address the listed patent through a Paragraph IV certification, a Paragraph III certification, or another statutory pathway.

Orange Book listing did not conclusively establish validity or infringement. It created the regulatory mechanism for early patent litigation and could delay approval after a timely infringement complaint. The FDA does not decide patent validity in the ANDA review process. [2,4]

Formulation and method-of-use protection

The PLIVA dispute should be distinguished from later Angiomax-related rights:

• The '404 patent principally provided active-ingredient and composition protection.
• Later patents addressed formulation quality, degradation products, stability, and manufacturing processes.
• Method-of-use claims may have applied to particular anticoagulation indications, but the public record for this docket does not establish that a separate method-of-use patent drove the PLIVA case.
• The litigation should not be characterized as a biosimilar dispute because bivalirudin is a chemically synthesized peptide drug approved through the ANDA pathway.

Did biosimilar risk affect the case?

No. Biosimilar risk was not the relevant regulatory issue.

Bivalirudin is not an antibody or other biologic requiring a 351(k) biosimilar application. PLIVA’s product was pursued through the ANDA pathway for a generic drug product. The relevant competitive risks were:

• Paragraph IV litigation;
• 30-month stay exposure;
• FDA approval timing;
• product quality and manufacturing compliance;
• potential launch at or after patent expiry; and
• price erosion following generic entry.

The case is therefore a conventional small-molecule or peptide ANDA patent dispute, not a biologics exclusivity dispute.

Which companies challenged Angiomax patents?

The Medicines Company faced broader generic competition involving bivalirudin from multiple manufacturers. The public patent record includes litigation involving companies such as Hospira and Mylan, but each case must be evaluated separately because different defendants may have challenged different patents and product characteristics.

Company	Relationship to Angiomax patent disputes
PLIVA-Hrvatska	Defendant in 1:09-cv-00751
Hospira	Defendant in later bivalirudin patent litigation involving formulation and manufacturing patents
Mylan	Involved in separate Angiomax-related litigation
The Medicines Company	Innovator and patent holder or rights holder

The existence of later Hospira or Mylan litigation does not convert those cases into precedent for the PLIVA docket. The claims, ANDA products, patents, and procedural records may differ.

What patent litigation affected generic bivalirudin entry?

The most important litigation effect was the use of the '404 patent to challenge PLIVA’s ANDA before expiration. The case created potential delay even though the patent’s remaining life was limited.

Later litigation increased the complexity of generic entry by asserting patents that were not limited to the original active ingredient. In particular, The Medicines Company pursued patents involving pharmaceutical formulation and manufacturing processes. The Federal Circuit later addressed issues arising from the Angiomax patent portfolio in litigation involving Hospira, including the on-sale bar and manufacturing-related patent rights. [5]

Those later decisions have commercial relevance because they illustrate how an innovator can attempt to protect a mature product after the basic composition patent approaches expiration. They do not establish the outcome of The Medicines Company’s claims against PLIVA.

What generic entry risks existed for Angiomax?

The principal risk was rapid price erosion after approval of a therapeutically substitutable generic bivalirudin product.

Regulatory risk

PLIVA required FDA approval of its ANDA. Approval could be delayed by:

• the statutory 30-month stay;
• unresolved patent litigation;
• deficiencies in chemistry, manufacturing, and controls;
• facility inspection issues;
• labeling requirements; or
• a tentative approval that did not permit commercial marketing.

Patent risk

The '404 patent presented a near-term barrier, but its expiration reduced the duration of protection. Later formulation or manufacturing patents could have created additional barriers if valid, enforceable, listed, and infringed by the proposed product.

Commercial risk

Generic bivalirudin could affect:

• Angiomax unit price;
• hospital contracting;
• group purchasing organization negotiations;
• procedure-level anticoagulant costs;
• share retention in percutaneous coronary intervention; and
• The Medicines Company’s revenue expectations.

The commercial exposure was more significant while Angiomax had limited direct competition. After generic entry, the branded product would face substitution and purchasing pressure even if the innovator retained some clinical or contracting advantages.

How does this case compare with later Angiomax patent litigation?

The PLIVA case was primarily an early generic-entry dispute involving the core bivalirudin patent. Later litigation shifted toward lifecycle-management patents.

Category	PLIVA case	Later bivalirudin litigation
Main issue	ANDA challenge to core patent protection	Formulation, manufacturing, and process protection
Patent profile	Earlier composition patent	Later-expiring lifecycle patents
Commercial timing	Near core patent expiry	Attempt to extend protection after core expiry
Regulatory setting	Standard ANDA Paragraph IV case	ANDA litigation involving additional product attributes
Reported merits precedent	None identified for PLIVA docket	Federal Circuit precedent in related cases
Biosimilar relevance	None	None

The strategic distinction is material. The PLIVA case addressed whether a generic could enter near the end of the original Angiomax patent term. Later litigation addressed whether technical controls over product manufacture and formulation could support additional exclusivity.

Key Takeaways

• The Medicines Company sued PLIVA-Hrvatska in Delaware in 2009 over an ANDA for generic bivalirudin.
• The principal asserted patent was U.S. Patent No. 5,196,404, covering bivalirudin-related compounds and compositions.
• The '404 patent was Orange Book-listed for Angiomax and was scheduled to expire in December 2010.
• The case was a Paragraph IV Hatch-Waxman action, not a biosimilar proceeding.
• The public docket does not show a reported merits judgment invalidating the patent or finding PLIVA’s product noninfringing.
• The dispute’s commercial value centered on approval and launch timing because the core patent was near expiration.
• Later Angiomax litigation involving formulation and manufacturing patents should be analyzed separately.
• No publicly reported record establishes detailed settlement economics or a definitive PLIVA launch date from this docket.

FAQs About The Medicines Company v. PLIVA-Hrvatska

Was U.S. Patent No. 5,196,404 the only patent asserted against PLIVA?

The public record identifies the '404 patent as the principal patent associated with the case. Later bivalirudin formulation and manufacturing patents were involved in separate litigation and should not automatically be attributed to the PLIVA action.

Did PLIVA invalidate the Angiomax patent?

No reported decision from the PLIVA docket establishes that PLIVA invalidated U.S. Patent No. 5,196,404. The case resolved without a reported merits judgment.

Could PLIVA launch generic bivalirudin before December 2010?

Only if it obtained FDA approval and overcame the patent-related stay or reached a settlement permitting earlier entry. Patent expiry alone did not guarantee immediate commercial launch because FDA approval and manufacturing requirements remained separate conditions.

Was Angiomax protected by pediatric exclusivity?

Any pediatric exclusivity applicable to Angiomax would have to be evaluated from the FDA product and exclusivity records in effect at the relevant time. The core commercial barrier in the PLIVA litigation was the Orange Book-listed patent and its remaining term.

What was the main business consequence of the PLIVA case?

The case created a mechanism to delay or control generic bivalirudin entry during the final period of the '404 patent. Its long-term impact was limited because the core patent was close to expiration and the docket produced no reported merits precedent.

References

1. U.S. District Court for the District of Delaware. (2009). The Medicines Company v. PLIVA-Hrvatska d.o.o., No. 1:09-cv-00751, docket records. CourtListener.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Patent and Trademark Office. (1993). U.S. Patent No. 5,196,404: Bivalirudin and analogues thereof.
4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
5. The Medicines Company v. Hospira, Inc., 827 F.3d 1363 (Fed. Cir. 2016).